ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have ACADIA with us this afternoon. We have Steve Davis, CEO; and Elena Ridloff, CFO.
And with that, I'm going to turn it over to Steve to make some opening comments.
Great. Thanks much, Salveen, and thanks to each of you for joining today. I just need to start with a brief reminder that the business of pharmaceutical development and commercialization has certain inherent risks, so please see a copy of our most recent SEC filings for a description of just how those risks relate to our business.
I'd like to briefly highlight today some of our key accomplishments so far this year, which will be a transformational year for ACADIA as we execute on our 3 strategic pillars. First, we will drive NUPLAZID growth in PDP. Our first quarter 2020 net sales were $90.1 million,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
